What is the clinical evidence from this study?

Study design: Review. Population: Acute coronary syndrome. Intervention: Low-molecular weight heparins (Enoxaparin) vs. Unfractionated heparin. Primary outcome: Clinical events.

What question did this study set out to answer?

Evaluate the clinical efficacy and superiority of enoxaparin and low-molecular-weight heparins compared to standard unfractionated heparin in managing acute coronary syndrome.

September 10, 2026Cardiovascular MedicineOpen Access

Niedermolekulare Heparine beim akuten Koronarsyndrom – ist Enoxaparin überlegen?

Q: What does this research mean for the field?

Low-molecular weight heparins, particularly enoxaparin, are superior to unfractionated heparin for reducing clinical events and play an increasingly important role in the pharmacological therapy of acute coronary syndrome. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

View Full Paper

Ask AI

Bookmark

Key result

Enoxaparin reduces clinical events versus UFH in patients with ACS.

Why the study?

To evaluate whether enoxaparin is superior to other antithrombotic therapies in acute coronary syndrome.

Does enoxaparin reduce clinical events compared to unfractionated heparin in patients with acute coronary syndrome?

Population

Patients with acute coronary syndrome (unstable angina and myocardial infarction)

Comparison

Low-molecular weight heparin (enoxaparin) vs Unfractionated heparin

Design

Review

Authors

LSLukas SpiekerImmunologie-Zentrum Zürich RCRoberto CortiInterventional Cardiology FRFrank RuschitzkaImmunologie-Zentrum Zürich

Discussion

Member takes

Implication

May support enoxaparin preference in ACS; leaves open need for updated trials versus contemporary regimens.

Key Points

Evaluate the clinical efficacy and superiority of enoxaparin and low-molecular-weight heparins compared to standard unfractionated heparin in managing acute coronary syndrome.
Review of clinical evidence and trial data regarding antithrombotic management strategies in acute coronary syndrome.
Analysis of risk stratification approaches using clinical presentation, electrocardiography, and troponin biomarkers.
Evaluation of findings from major randomized trials, including the ESSENCE study, assessing enoxaparin versus unfractionated heparin.
Low-molecular-weight heparins demonstrate established efficacy in reducing adverse clinical outcomes in acute coronary syndrome.
Enoxaparin demonstrated clinical superiority over unfractionated heparin for the reduction of adverse clinical events in the ESSENCE trial.

Structured PICO

Does enoxaparin reduce clinical events compared to unfractionated heparin in patients with acute coronary syndrome?

Population

Patients with acute coronary syndrome (unstable angina and myocardial infarction)

Intervention

Low-molecular weight heparin (enoxaparin)

Comparator

Unfractionated heparin

Outcome

Clinical events

Low-molecular weight heparins, specifically enoxaparin, play an increasingly important role in the pharmacologic therapy of acute coronary syndrome due to their superiority over unfractionated heparin.

Cite This Study

Spieker et al. (2003) conducted a review in Acute coronary syndrome. Low-molecular weight heparins (Enoxaparin) vs. Unfractionated heparin was evaluated on Clinical events. Enoxaparin was superior to unfractionated heparin for the reduction of clinical events in patients with acute coronary syndrome.

synapsesocial.com/papers/6aa269eaa1e750260650a00d https://doi.org/10.3390/cardiovascmed6060048

View Full Paper

Ask AI

Bookmark

Niedermolekulare Heparine beim akuten Koronarsyndrom – ist Enoxaparin überlegen?

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Niedermolekulare Heparine beim akuten Koronarsyndrom – ist Enoxaparin überlegen?

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider